Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 4

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 4
---
 The selling shareholders may sell all
or a portion of the common shares from time to time in market transactions through any market on which our common shares are then traded,
in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at
negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of
sale. We will bear all of the expenses incurred in connection with the registration of these shares. The selling shareholders will pay
any underwriting discounts and selling commissions and/or similar charges incurred in connection with the sale of the shares. We will
not receive any proceeds from the sale of the common shares by the selling shareholders. All net proceeds from the sale of the common
shares covered by this prospectus will go to the selling shareholders. See “Plan of Distribution” on page 24 of this prospectus.

Our common shares are currently
traded on the Nasdaq Capital Market, or Nasdaq, under the symbol “CMND.” On September 18, 2025, the last reported sale price of
our common shares on the Nasdaq was $1.00.

Our common shares also trade
on the Frankfurt Stock Exchange, or FSE, under the symbol “CWY”. On September 18, 2025, the last reported sales price of our common
shares on FSE was EUR 0.8690 (approximately $1.02) per share.

We are both an emerging growth
company, as defined in the Jumpstart Our Business Startups Act of 2012 (or the JOBS Act), and a “foreign private issuer,”
as defined under the U.S. federal securities law and are subject to reduced public company reporting requirements. See “Prospectus
Summary – Implications of Being an Emerging Growth Company and Foreign Private Issuer” for additional information.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 6.

Neither the SEC nor the Canadian Securities Exchange, nor any state or other foreign securities commission has approved nor disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is ,
2025.

TABLE OF CONTENTS</div>

| PROSPECTUS SUMMARY                                |     |  1 |
| THE OFFERING                                      |     |  5 |
| RISK